Amgen introduces new rheumatoid arthritis book and first online resource for access to interleukin-1 (IL-1) research

October 28, 2000

THOUSAND OAKS, Calif., October 30, 2000 -- Amgen (NASDAQ:AMGN) today announced the introduction of and Proinflammatory and Anti-Inflammatory Cytokines in Rheumatoid Arthritis: A Primer for Clinicians, two new resources designed to provide health care professionals with updated, reliable and comprehensive information about the role of cytokines, specifically interleukin-1 (IL-1), in rheumatoid arthritis (RA). is the first Web site with the latest scientifically rigorous clinical data regarding IL-1 in RA. As 65 percent of physicians -- more than twice as many as four years ago -- use the Internet to access medical research today , the Web site provides a quick and easy way for rheumatologists to keep informed about new research through a medium many already utilize.

"There is mounting evidence that IL-1 plays a fundamental role in the disease progression of rheumatoid arthritis," said Keith Leonard, vice president of rheumatology marketing at Amgen. "As the only online resource about IL-1, meets a need for rheumatologists and other health care professionals who want access to the latest research. It is another example of Amgen's commitment to research and scientific exchange in the area of rheumatology."

The Web site consists of access to published materials, including relevant articles and abstracts, plus the new expanded version of the popular Proinflammatory and Anti-Inflammatory Cytokines in Rheumatoid Arthritis: A Primer for Clinicians. This book, authored by Dr. Charles A. Dinarello, professor of medicine at the University of Colorado School of Medicine, is intended to familiarize general health care professionals, as well as rheumatologists, with aspects of cytokine biology as they relate to the understanding of rheumatoid arthritis in humans.

The field of cytokine biology is rapidly expanding and the primer offers insight into the groundbreaking clinical work leading to the discovery of new cytokines. Research has shown that dysregulation of immune parameters in rheumatoid arthritis often correlates with cytokine abnormalities. Animal models have yielded vital preclinical information on the role of cytokines in the progression of rheumatoid arthritis and the potential for novel, anticytokine-based therapies.

Other Web site highlights include:
Amgen, Thousand Oaks
Rebecca Hamm, 805/447-3872 (media)
Cary Rosansky, 805/447-4634 (investors)

Amgen is dedicated to developing new and important therapies for rheumatoid arthritis. Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology.

Porter Novelli

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to